Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.

Johannes Duell; Kami J. Maddocks; Eva González-Barca; Wojciech Jurczak; Anna Marina Liberati; Sven De Vos; Zsolt Nagy; Aleš Obr; Gianluca Gaidano; Pau Abrisqueta; Nagesh Kalakonda; Marc André; Martin Dreyling; Tobias Menne; Olivier Tournilhac; Marinela Augustin; Andreas Rosenwald; Maren Dirnberger-Hertweck; Johannes Weirather; Sumeet Ambarkhane; Gilles Salles

doi:10.3324/haematol.2021.279802

Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.

Johannes Duell, Kami J. Maddocks, Eva González-Barca, Wojciech Jurczak, Anna Marina Liberati, Sven De Vos, Zsolt Nagy, Aleš Obr, Gianluca Gaidano, Pau Abrisqueta, Nagesh Kalakonda, Marc André, Martin Dreyling, Tobias Menne, Olivier Tournilhac, Marinela Augustin (Co-author), Andreas Rosenwald, Maren Dirnberger-Hertweck, Johannes Weirather, Sumeet AmbarkhaneGilles Salles

Department of Internal Medicine V, Division of Oncology and Hematology

Research output: Contribution to journal › Correction › peer-review

88 Citations (Web of Science)

Original language	English
Journal	HAEMATOLOGICA
DOIs	https://doi.org/10.3324/haematol.2021.279802
Publication status	Published - 2021

Keywords

MULTICENTER
TRIAL

Access to Document

10.3324/haematol.2021.279802

Cite this

Duell, J., Maddocks, K. J., González-Barca, E., Jurczak, W., Liberati, A. M., De Vos, S., Nagy, Z., Obr, A., Gaidano, G., Abrisqueta, P., Kalakonda, N., André, M., Dreyling, M., Menne, T., Tournilhac, O., Augustin, M., Rosenwald, A., Dirnberger-Hertweck, M., Weirather, J., ... Salles, G. (2021). Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. HAEMATOLOGICA https://doi.org/10.3324/haematol.2021.279802

Duell, Johannes ; Maddocks, Kami J. ; González-Barca, Eva et al. / Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. In: HAEMATOLOGICA 2021.

@article{dd164cfe5ae54b2e917c6b4e337fa99a,

title = "Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.",

keywords = "MULTICENTER, TRIAL",

author = "Johannes Duell and Maddocks, {Kami J.} and Eva Gonz{\'a}lez-Barca and Wojciech Jurczak and Liberati, {Anna Marina} and {De Vos}, Sven and Zsolt Nagy and Ale{\v s} Obr and Gianluca Gaidano and Pau Abrisqueta and Nagesh Kalakonda and Marc Andr{\'e} and Martin Dreyling and Tobias Menne and Olivier Tournilhac and Marinela Augustin and Andreas Rosenwald and Maren Dirnberger-Hertweck and Johannes Weirather and Sumeet Ambarkhane and Gilles Salles",

note = "Augustin: Department of Hematology and Oncology, Paracelcus Medical University, Klinikum N{\"u}rnberg, N{\"u}rnberg",

year = "2021",

doi = "10.3324/haematol.2021.279802",

language = "English",

journal = "HAEMATOLOGICA ",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

}

Duell, J, Maddocks, KJ, González-Barca, E, Jurczak, W, Liberati, AM, De Vos, S, Nagy, Z, Obr, A, Gaidano, G, Abrisqueta, P, Kalakonda, N, André, M, Dreyling, M, Menne, T, Tournilhac, O, Augustin, M, Rosenwald, A, Dirnberger-Hertweck, M, Weirather, J, Ambarkhane, S & Salles, G 2021, 'Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.', HAEMATOLOGICA https://doi.org/10.3324/haematol.2021.279802

Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. / Duell, Johannes; Maddocks, Kami J.; González-Barca, Eva et al.
In: HAEMATOLOGICA , 2021.

Research output: Contribution to journal › Correction › peer-review

TY - JOUR

T1 - Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.

AU - Duell, Johannes

AU - Maddocks, Kami J.

AU - González-Barca, Eva

AU - Jurczak, Wojciech

AU - Liberati, Anna Marina

AU - De Vos, Sven

AU - Nagy, Zsolt

AU - Obr, Aleš

AU - Gaidano, Gianluca

AU - Abrisqueta, Pau

AU - Kalakonda, Nagesh

AU - André, Marc

AU - Dreyling, Martin

AU - Menne, Tobias

AU - Tournilhac, Olivier

AU - Augustin, Marinela

AU - Rosenwald, Andreas

AU - Dirnberger-Hertweck, Maren

AU - Weirather, Johannes

AU - Ambarkhane, Sumeet

AU - Salles, Gilles

N1 - Augustin: Department of Hematology and Oncology, Paracelcus Medical University, Klinikum Nürnberg, Nürnberg

PY - 2021

Y1 - 2021

KW - MULTICENTER

KW - TRIAL

U2 - 10.3324/haematol.2021.279802

DO - 10.3324/haematol.2021.279802

M3 - Correction

C2 - 34407608

SN - 0390-6078

JO - HAEMATOLOGICA

JF - HAEMATOLOGICA

ER -

Duell J, Maddocks KJ, González-Barca E, Jurczak W, Liberati AM, De Vos S et al. Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. HAEMATOLOGICA . 2021. doi: 10.3324/haematol.2021.279802